Product Name: Relugolix CAS NO: 737789-87-6
Chemical & Physical Properties
Appearance : White powder.
Assay : ≥99.0%
Relugolix (INN) (developmental code name TAK-385) is a non-peptide, orally-active, selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (IC50 = 0.12 nM) that is under development for clinical use by Takeda. It is currently in phase II clinical trials for the treatment of endometriosis, uterine leiomyoma, and prostate cancer.
A single oral administration of relugolix at a dose of 3mg/kg has been found to suppress luteinizing hormone levels for more than 24 hours in castrated cynomolgus monkeys, indicating a long duration of action. The drug (80–160mg/day) has been found to reduce testosterone levels to sustained castrate levels in men with once-daily chronic administration. Lower dosages (10–40mg/day) are being studied in the treatment of endometriosis and uterine leiomyoma to achieve partial sex hormone suppression. The reasoning behind partial suppression for these conditions is to reduce the incidence and severity of menopausal symptoms such as hot flushes and to avoid bone mineral density changes caused by estrogen deficiency that can eventually lead to osteoporosis.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.